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Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease and can be the first step of the atopic
march.
Objective: In this retrospective study, we analysed the immunological and clinical patterns of AD in a group of
children affected by the disease since their first years of life, in order to evaluate if and how these patterns can
change over time, and to identify biomarkers that can possibly correlate with the clinical phenotype.
Methods: We enrolled Caucasian children with diagnosis of AD performed by a specialist on the basis of Hanifin
and Rajka’s criteria and with a first clinical and laboratory evaluation before 5 years of age. Patients were divided in
2 groups: IgE-associated AD (with or without allergic respiratory diseases) and non-IgE-associated AD.
Results: Among 184 patients enrolled in this study, at the beginning 30/184 were classified as having
non-IgE-associated AD, but during follow-up, at the median age of 36 months, 15 patients became allergic. All 15
patients who switched from the non-IgE to the IgE-associated form had a significantly earlier onset of AD than
those who did not switch. Dust mite sensitization seem to be the best biomarker (OR 2.86) to predict the appearance
of allergic respiratory diseases.
Conclusion: IgE-associated AD is more frequent in childhood than non-IgE-associated AD. These two phenotypes
are different in the age of onset and in the remission patterns. In the first years of life, it is important to distinguish
the different phenotypes in order to evaluate possible allergic related conditions.
Keywords: Atopic dermatitis, Phenotypes, Allergy, Childhood, Atopic marchIntroduction
Atopic dermatitis (AD) is a chronic inflammatory skin
disease that affects between 15% to 30% of the pediatric
population with differences according to age [1,2]. The
presence of an epidermal barrier dysfunction and an
alterated immunoallergic profile contribute to AD pa-
thogenesis [3,4]. Filaggrin mutations, other genetically
transmitted skin barrier defects, as well as environmen-
tal factors, form the basis for the clinical heterogeneity
of the disease [5,6].
Food allergy is more common in children with AD
than in the general population, being present in 15-30%
of these patients [7-9]. Moreover AD, especially the
early-onset kind, could represent the first step of the
atopic march [10,11] and it is a major risk factor for the
development of asthma; and patients with specific IgE* Correspondence: giampaolo.ricci@unibo.it
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unless otherwise stated.antibodies to common environmental allergens present a
higher risk for progressing in the atopic march to re-
spiratory allergic diseases, such as rhinitis and asthma,
than those without IgE sensitization. These diseases may
appear subsequently to or more rarely simultaneously
with AD [12,13]. The adaptive immune response in AD
is associated with increased expression of the TH2 cyto-
kines (IL-4, IL-13 and IL-31) during the acute phase of
AD, while in the chronic phase also TH1 polarization is
present [14].
Despite its high incidence, previous studies that inves-
tigated the different immunological parameters of AD,
such as total and specific IgE (sIgE) serum levels, have
shown a heterogeneity of results probably due to diffe-
rent patient selection criteria and to an inhomogeneous
determination of the allergometric tests [15-24].
Several systemic and cutaneous immune abnormalities
have been previously described in AD [25]. Among
them, an abnormal Th2-polarization of the immune re-
sponse [26] might play a pivotal role and has also beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ma and allergies.
Recently, a biological model has been proposed in
order to try to identify the links between AD genotype
and the endophenotype [27], and, possibly, to develop
distinctive preventive measures and personalized thera-
peutic approaches [28]. A better understanding of the
different AD phenotypes is very important to this re-
spect [29].
The primary endpoint of this retrospective follow-up
study is to analyze the immunological and clinical pat-
terns of AD in a group of children affected by the dis-
ease since their first years of life. Other endpoints are 1)
to evaluate if and how these patterns can change over
time and 2) to identify the presence of biomarkers that
can possibly correlate with the clinical phenotype.
Materials and methods
Study population and inclusion criteria
The present report represents the retrospective prelim-
inary stage of a study named “AllerGene2” that aims at
correlating AD phenotypes to genetic features, in par-
ticular IgE and non-IgE-associated forms.
We enrolled Caucasian children with AD referred to
the Pediatric Dermatology (Dermatology Unit) and
Pediatric Allergology (Pediatric Unit) Outpatient Clinics
of S. Orsola-Malpighi University Hospital in Bologna
from 2006 to 2011. Patients involved in this study had
already been included in the normal clinical routine of
these departments.
Patients were enrolled if the following inclusion cri-
teria were fulfilled:
a) an informed consent signed by the parents;
b) an age between 0 and 18 years;
c) a first clinical and laboratory evaluation at ≤5 years
of age;
d) a diagnosis of AD performed by a specialist of the
team based on the criteria of Hanifin and Rajka [30];
e) a mean retrospective follow-up of 10 years.
Patients were excluded if they suffered from a systemic
disease (other than asthma or allergy) or in the absence
of parents’ consent.
All the included patients were required to have per-
formed, either for AD evaluation or for food allergy,
asthma and allergic rhinitis follow-up, a complete aller-
gometric assessment defined by skin prick test (SPT)
and total and s-IgE.
Clinical assessment
At the time of the first evaluation, AD severity was
assessed by means of the objective SCORAD [31]. We
considered AD mild when the objective SCORAD waslower than 20 points, moderate between 20 and 39, se-
vere 40 points or more.
At each visit, when clinically appropriate, allergometric
tests were performed to define the AD phenotype: SPT
for common inhalant and food allergens and/or total
and sIgE serum level.
We considered AD as IgE-associated if at least one of
the following criteria was observed:
1. clinical symptoms of allergic diseases (asthma and/or
rhinoconjunctivitis and/or food allergy);
2. positive SPT for food or inhalant allergens;
3. elevated level of total IgE according to age [32];
4. presence of sensitization for food or inhalant
allergens (sIgE measured by ImmunoCAP method).
On the contrary, we defined non-IgE-associated AD if
none of the previous criteria was satisfied [33].
The group with IgE-associated AD was further divided
into 2 subgroups: 1) patients with allergic respiratory
symptoms and 2) patients without allergic respiratory
symptoms. The mean follow-up time from AD diagnosis
to inclusion in the present analysis was 10 years.Allergometric assessment
SPT (extracts by Lofarma, Italy) were performed for the
most common food (cow’s milk, hen’s egg, soybean,
wheat, peanut, nut, codfish, apple) and inhalant allergens
(grass pollens; D. pteronyssinus; D. farinae; dog and cat
dander; Alternaria a.) and for history-oriented allergens.
The total IgE serum level was determined with ELISA
and was compared with the normal value for age [32].
The determination of sIgE was performed by Immuno-
CAP™ FEIA (Phadia, Sweden) in all patients for the same
allergens as above. A patient was considered as sensi-
tized when having sIgE levels higher than 0.70 kU/L for
food allergens, and higher than 0.35 kU/L for inhalant
allergens. We assumed a different and higher cut-off
value for food allergens because weak positive values of
sIgE for the main foods (cow’s milk, hen’s egg, wheat)
may occur in the first years of life even in normal sub-
jects, according to the results of the Danish Allergy
Research Center cohort [34].Statistical methods
Standard statistical descriptions of parameters were used
to characterize the data (mean, median and range). The
outcomes of persistence or remission of AD were evalu-
ated in the different groups and graphically represented
using the method of Kaplan and Meier. Student t test
was performed to compare means between groups. All P
values were 2-sided and values less than 0.05 were con-
sidered as statistically significant.
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2007 for Windows 7 and GraphPad QuickCalcs Online
Calculators for Scientists [35].
Ethical aspects
The AllerGene2 study was approved by the S. Orsola-
Malpighi Hospital Ethics Commettee on 10th May 2011
protocol n. 40/2011/U/Tess.
Results
A total of 184 patients entered the study. At time 0, that is
the first clinical and laboratory evaluation, 99 patients were
aged under 2 years and 85 patients were between 2 and
5 years. At the first clinical evaluation 35 children (19%) had
mild AD, 112 (61%) moderate AD and 37 (20%) severe AD.
30/184 (16%) had been classified as having non-IgE-
associated AD. Among these 30 non-IgE AD patients, at
a median age of 36 months, 15 children became allergic,
so that at time 1, after a mean follow-up of 10 years, of
the total 184 patients, 169 (92%) were classified as ha-
ving IgE-associated and 15 (8%) non-IgE-associated AD.
All 15 patients who switched from the non-IgE- to the
IgE-associated form had an early onset of AD and had
been first referred to our Clinics before the age of 2; in
particular, 4 children switched between the first and se-
cond year of life, 6 patients between the second and
third year, 4 between the fourth and the seventh, and the
last one before the eighth year (Figure 1).
At the end of the follow-up 169 (92%) were diagnosed
with IgE-associated AD and 15 (8%) with the non-IgE-
associated form; the main clinical characteristics are
reported in Table 1. The mean age of onset and of re-
mission of AD was significantly different between the 2Figure 1 Switch from non-IgE to IgE-associated AD in 99 children stu
age of 8 years.phenotypes: respectively 8 months vs 30 months (p =
0.0001) for onset, 61 months vs 119 months for remis-
sion (p = 0.0003).
AD course was longer in children affected by non-IgE-
associated AD: in particular, it persisted in more than
90% (14/15) of patients at 60 months of life and in about
67% (10/15) of patients at 120 months (10 years). In the
IgE-associated form, remission occurred earlier (Figure 2);
in those patients without respiratory symptoms, AD was
present in roughly 70% of children at 60 months of life
and in less than 20% of patients at 120 months.
Moreover, the geometric mean values of total IgE in-
creased year by year in IgE-associated AD, whereas in
the non-IgE-associated form the total IgE level remained
constantly low over time (Figure 3).
The IgE-associated group was divided into 2 sub-
groups (Table 1):
a) group 1, with respiratory allergy (N 131, 78%), in
which asthma was present in 62 patients (47%, mean
age at onset 6 years) and rhinoconjunctivitis in 112
(86%, mean age at onset 6 years);
b) group 2, without respiratory allergy (N 38, 22%).
The mean age of AD remission was 65 months in group
1 and 36 months in group 2 (p = 0.0146); moreover the
mean age of food allergy remission was 55 months in
group 1 and 37 months in group 2 (p = 0.035) (Table 1).
The mean values of sIgE against the main food and in-
halant allergens at different ages are reported in Table 2.
Subjects with respiratory diseases showed higher levels
of total and sIgE for inhalant allergens; in particular,
dust mites were higher both in absolute value and indied before 2 years of age. The switch happened in all cases by the
Table 1 Main clinical features of 184 children affected by AD after a mean 10-year follow-up





Patients N (%) 15 (8%) 169 (92%) 131 (78%) 38 (22%) 184
M (%) 7 (47%) 95 (56%) 74 (56%) 21 (55%) 102 (55%)
Family history of atopy N (%) 10 (67%) 120 (71%) 94 (72%) 26 (68%) 130 (71%)
Family history of AD N (%) 1 (7%) 23 (14%) 19 (15%) 4 (11%) 24 (13%)
Mean age at AD onset (months) 30 * 8 * 8 7 10
Mean age of AD remission (months) 119 ** 61 ** 65 $ 36 $ 66
Past or present food allergy/OAS / 125 (74%) 94 (72%) 31 (82%) 125 (68%)
Mean age at food allergy/OAS onset (months) / 16 18 9
Mean age at food allergy/OAS remission (months) / 49 55 $$ 37 $$
Wheezing / 53 (31%) 53 (40%) / 53 (29%)
Asthma / 62 (37%) 62 (47%) / 62 (34%)
Allergic Rhinitis N (%) / 112 (66%) 112 (85%) / 112 (61%)
*P value = 0.0001; **P value = 0.0003; $P value = 0.0146; $$ P value = 0.035.
IgE-associated AD (169 children) was divided in 2 subgroups: 1) with allergic respiratory symptoms (131 children); 2) without allergic respiratory symptoms (38
children). OAS = oral allergy syndrome.
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with inhalants sensitization in the first 3 years of life,
have a higher risk to be affected by respiratory allergy
in later years (dust mite sensitization OR 2.86; grass
pollen OR 1.66).
The results of SPT did not influence the definition of
the patient’s phenotype; i.e. all patients with at least one
positive SPT had at least one positive sIgE, and all the
patients with negative SPT had negative sIgE.Figure 2 AD remission over time (Kaplan-Meier graph). “Total” represe
divided between children with (N = 131) and without (N = 38) allergic respDiscussion
Although many clinical and laboratory studies have
tried to understand AD and the progression of the
atopic march, few data exist in order to determine the
different phenotypes of AD. In a previous review,
Schmid-Grendelmeier et al. [15]. reported the presence
of many differences between non-IgE-associated and
IgE-associated AD: in particular, data about the preva-
lence of the non-IgE-associated form in the pediatricnts all the included patients (N = 184); IgE-associated AD (N = 169) was
iratory diseases; non-IgE-associated AD (N = 15).
Table 2 Geometric mean (GM) of total (UI/mL) and specific (kU/L) IgE, and percentage of positivity in children with
IgE-associated AD phenotype at different ages
IgE-mediated AD with respiratory diseases
Months 0-12 13-24 24-36 36-48 48-60 61-72 73-84
(N = 25) (N = 51) (N = 49) (N = 45) (N = 53) (N = 59) (N = 47)
IgE (UI/mL) 64 128 232 260 306 367 549
sIgE (kU/L) GM % GM % GM % GM % GM % GM % GM %
Cow’s milk 6.2 48 3.0 63 2.4 69 1.6 53 2.0 42 2.0 37 2.1 38
Hen’s egg (white) 7.3 76 5.8 76 4.8 73 3.5 67 2.6 57 1.7 42 2.4 40
Phleum p. 0.8 12 1.4 14 2.0 47 4.7 69 8.3 72 13.5 63 16.9 87
Cynodon d. 0 2.3 6 1.6 38 3.0 51 3.7 60 7.2 49 9.4 81
D. pteronyssinus 1.1 12 1.5 10 4.0 18 5.5 40 8.0 40 9.1 39 11.0 53
D. farinae 0.5 8 1.1 10 2.6 22 6.9 40 8.5 34 7.3 37 13.7 49
IgE-mediated AD without respiratory diseases
Months 0-12 13-24 24-36 36-48 48-60 61-72 73-84
(N = 13) (N = 25) (N = 25) (N = 16) (N = 15) (N = 11) (N = 6)
IgE (UI/mL) 87 136 180 285 276 199 235
sIgE (kU/L) GM % GM % GM % GM % GM % GM % GM %
Cow’s milk 3.7 69 6.6 56 5.1 60 5.2 62 1.9 53 9.5 36 52.0 33
Hen’s egg (white) 6.8 92 4.8 72 2.7 56 2.1 62 2.2 73 1.6 45 0.7 33
Phleum p. 0 0.5 12 3.1 24 6.2 50 4.9 47 24.8 54 13.8 33
Cynodon d. 0 0.5 16 1.9 20 3.5 50 4.7 40 10.1 54 4.4 33
D. pteronyssinus 0 0.4 4 0.6 8 1.1 25 1.7 33 3.9 36 8.1 33
D. farinae 0 0.4 4 1.1 8 1.6 19 1.7 33 4.0 36 5.6 33
The patients are divided into 2 groups according to the presence (group 1) or absence (group 2) of allergic respiratory diseases. Total and specific IgE were
periodically performed according to the patients’ needs.
Figure 3 Mean levels of total serum IgE (UI/mL) over time in the different groups. Geometric means are plotted as logarithms.
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Kalinke et al. [16] who studied 22 children aged 1–5
years, to 45% observed in the paper of Cabon et al. [20]
in 59 children aged 0–12 years. In 1999, Schäefer et al.
[23]. reported 25% of non-IgE-associated AD forms in
an epidemiological study on 2201 children aged 5–14
years.
On the other hand, Palmer et al. [24]. observed that
around 80% of infants with AD exhibit increased total
serum IgE levels.
Our data support the concept of the high frequency of
IgE-associated AD in children (N. 169/184, 92%). This
value can, however, be partially biased by the preliminary
selection of the patients that are normally referred to us.
Children with mild AD are rarely referred to a third-
level allergological or dermatological clinic, because they
are usually treated by the primary care pediatrics and
only the more severe or persistent forms need a deeper
clinical, dermatological and allergological evaluation.
This might explain the fact that only a fifth of our chil-
dren presented a mild form of AD: the majority of them
had moderate or severe forms, in which an allergic back-
ground coexists very frequently, mainly when the child
is affected by recurrent wheezing.
An interesting point raised by our study is that pa-
tients without an allergic sensitization should be con-
sidered as having a non-IgE-associated form around
school-age and not earlier: most of the 15 children who
passed from a non-IgE-associated to an IgE-associated
form switched in the first 3 years of life and all of them
within the seventh year (Figure 1). Other authors [36,37]
have previously mentioned the possibility of a switch
from non-IgE- to IgE-associated AD, especially in the
first years of life and only rarely afterwards.
Some clinical characteristics of non-IgE-associated AD
reported in this study are similar to those reported in
previous studies: [15,38-42] for example, the later onset
and the delayed remission; whereas there is no signifi-
cant difference in the family history compared to IgE-
associated AD.
According to our data, in order to define the form of
AD, it might be sufficient to determine only one para-
meter between sIgE and SPT, excluding total IgE [43]:
certainly, sIgE are more sensitive, in particular for inha-
lant allergens in the first years of life, but in our study
when only SPT were performed, the patients distribution
between IgE and non-IgE-associated AD did not change,
because of multiple inhalant and/or food sensitizations
in the majority of children.
All the patients who switched from non IgE- to IgE-
associated AD forms were studied in the first 2 years
of life. We feel it important to emphasize that IgE-
associated AD has an early onset age (mean age 8 months
vs 30 months of non-IgE-associated form), supporting thehypothesis that the allergen may penetrate through the in-
flamed skin of the child and initiate the allergic response
[3,44].
A complete remission of skin symptoms (in about 50%
of patients) was observed around 6–7 years of age in the
whole group, confirming the previous data by Einchenfield
et al. [45]. that reported between 40-60% of AD remission
at the age of 7.
We observed that in patients with IgE-associated AD,
total and sIgE levels grow steadily with age, for the de-
velopment of respiratory and/or food allergies, whereas
in the other form, total IgE remain low and stable over
time (Figure 3 and Table 2).
Furthermore, because the IgE-associated AD group
was much larger, we attempted to define another clinical
phenotype by correlating the presence of respiratory
allergy with other possible/probable biomarkers. We
distinguished patients with allergic respiratory diseases
(group 1) from those without allergic respiratory dis-
eases (group 2): at the same age of follow-up, even
though AD remission cases are overlapping, the mean
age of AD remission is statistically lower in the subgroup
without respiratory allergies (36 months vs 65 months,
P = 0.0146) (Figure 2); a possible explanation for this
difference might be that during the pollen season, in
the presence of rhinitis or asthma, there could be a
worsening of AD.
Patients with allergic respiratory diseases show a higher
concentration and percentage of sIgE for inhalant aller-
gens than those in group 2, with sensitizations only
against inhalants (Table 2). These early sensitizations to
grass pollens and mainly to mites can represent a signifi-
cant biomarker, predicting the appearance of respiratory
diseases, especially asthma.
The onset of food allergy in the first years of life is re-
lated to the presence of cow’s milk and/or hen’s egg
sensitization, as confirmed by high sIgE levels for these
allergens in both groups (Table 2); later, in the subgroup
with respiratory diseases, most cases of immediate symp-
toms after food ingestion are due to oral allergy syndrome
to fruits and vegetables which include allergens that cross-
react with pollens (data not shown).
Clinical AD phenotypes evolve during the first years of
life so that it is difficult to frame each patient into a de-
finite classification until a sufficient follow-up period has
been reached. It is not yet possible to predict if the pa-
tients with only food allergy symptoms, but sensitized to
inhalant allergens, will also develop respiratory symp-
toms in the following years, as well as we cannot predict
if a patient with only allergic rhinitis and high levels of
sIgE will also develop asthma. In line with what was sug-
gested by Bieber et al. [27],. the correlation with different
genotypes will maybe suggest some additional data in
order to understand the complexity of the mechanisms
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link them to specific biomarkers.
A bias of our study is that some patients with mild
AD were not followed up for a sufficient time and were
not included in this study, so that our conclusions are
especially addressed to moderate to severe AD.
Our study shows that IgE-associated AD is more fre-
quent in childhood than non-IgE associated AD and that
these two phenotypes are different in the age of onset,
which is usually later in the case of the non-IgE forms,
and in the remission patterns, since IgE-associated AD
seems to remit earlier and more frequently than the
other form.
In the first 3 years of life, it is useful to evaluate the
atopic condition in moderate-to-severe AD, and SPT are
often sufficient to distinguish between the IgE- and non
IgE-associated forms. In particular, it is important to pay
attention to the sensitization for dust mites in the first
3 years of life, because it is a possible marker for sub-
sequent appearance of allergic respiratory diseases.
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